The new analysis, published in JACC: Heart Failure, included data from 75 different studies.

The small study, published in the Journal of the American College of Cardiology, compared patient outcomes associated with metoprolol and a placebo. 

Patients taking SGLT2 inhibitors were 22% less likely to die from heart-related causes.

This latest analysis tracked more than 300 patients for a median follow-up period of nearly five years.

The scores can help predict a patient's short- and long-term risk of adverse outcomes. 

Patients with HIV have a greater chance of developing heart failure, according to new data published in Mayo Clinic Proceedings.

The study included more than 200,000 MI survivors—and nearly 25% presented with one form of renal failure or another. 

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin.